COMPANY

Arsenal Biosciences

Keywords: oncology Recurrence Metastatic Castration Resistant Prostate Cancer Ovarian Epithelial Carcinoma Ovarian Neoplasms Fallopian Tube Neoplasms Peritoneal Neoplasms Glandular and Epithelial Neoplasms Ovarian Diseases Female Genital Neoplasm Abdominal Neoplasm Advanced/Metastatic Clear Cell Renal Cell Carcinoma AB-3028 AB-1015 AB-2100

Profile checked Oct 10, 2026

3Trials (company is sponsor)

Raises and deals from press releases

Deal Deal · amount not disclosed · announced Jan 13, 2025 Company release ↗
Source quote
- Jan 13, 2025 · Company release ↗
  “Bristol Myers Squibb exercises an exclusive license option for ArsenalBio’s AB-4000 series programs”
Raise Series C · $325M · announced Sep 4, 2024 Company release ↗
Source quote
- Sep 4, 2024 · Company release ↗
  “(ArsenalBio), a clinical stage programmable cell therapy company focused on engineering advanced CAR T-cell therapies for solid tumors, today announced the close of an oversubscribed $325 million Series C financing round.”

Raises announced in these releases: $325M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Timeline

Jan 9, 2026 Trial start Phase 1/Phase 2: AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC) source ↗
Sep 4, 2024 Raise Series C · $325M source ↗
Feb 26, 2024 Trial start Phase 1/Phase 2: AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC) source ↗
Nov 29, 2022 Trial start Phase 1: AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer source ↗

Upcoming milestones

2029-05 (ESTIMATED) · Phase 1/Phase 2 · AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC) · NCT07285694

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 3

Record	Title	Phase	Status	Start	Primary completion
NCT07285694	AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)	Phase 1/Phase 2	Active, not recruiting	Jan 9, 2026	2029-05 (estimated)
NCT05617755	AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer	Phase 1	Active, not recruiting	Nov 29, 2022	Sep 30, 2024 (actual)
NCT06245915	AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC)	Phase 1/Phase 2	Active, not recruiting	Feb 26, 2024	Mar 31, 2026 (estimated)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

InvestorListed in the portfolio of ARCH Venture Partners (captured Oct 12, 2026). portfolio page ↗